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nohistochemistry.  Results: Compared with unaffected mu-
cosa, BCRP expression was significantly reduced in inflamed 
mucosa of newly diagnosed drug-naïve patients with UC 
(expression reduced to 30%) as well as in patients not re-
sponding to treatment (reduced to 25%) with either 5-ami-
nosalicylates (n = 7) or prednisone (n = 4). Unaffected mu-
cosa of UC patients showed comparable transporter ex-
pression to unaffected mucosa of control subjects. MDR1 
expression depicts a similar pattern. Protein staining for Pgp 
and BCRP was significantly reduced in the inflamed mucosa 
of patients with active UC.  Conclusions: Expression of both 
efflux transporters BCRP and MDR1 is reduced, but only in 
inflamed tissue of patients with active UC. Transporter ex-
pression in unaffected mucosa of patients with active UC is 
comparable to healthy controls. The data suggest that the 
inflammatory process is responsible for the reduced levels. 
A major role in the pathogenesis of UC is unlikely. 
 Copyright © 2008 S. Karger AG, Basel 
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 Abstract 
 Aims: Efflux transporters such as breast cancer resistance 
protein (BCRP/ABCG2) and P-glycoprotein (Pgp; MDR1/
ABCB1) are protecting the enterocytes from potentially toxic 
compounds. Both transporters have been reported to be 
downregulated in patients with active ulcerative colitis (UC). 
The aim of this study was to evaluate transporter expression 
in both unaffected and inflamed mucosa of patients with ac-
tive UC, in drug-naïve and treated patients with UC and com-
pare the results with transporter expression in healthy sub-
jects. Methods: Transporter expression was determined 
with real-time RT-PCR (TaqMan) in inflamed and unaffected 
mucosa of newly diagnosed (n = 12) and therapy-refractory 
(n = 11) patients with UC. Expression levels were compared 
with UC patients in remission (n = 11) and control subjects
(n = 26). BCRP and Pgp expression was evaluated by immu-
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 Introduction 
 Breast cancer resistance protein (BCRP/ABCG2) as 
well as P-glycoprotein (Pgp; MDR1/ABCB1) are members 
of the ATP-binding cassette (ABC) transporter family. 
Both were first detected in multi-drug resistant tumor 
cells  [1, 2] . Both have a protective function against poten-
tially toxic xenobiotics and are highly expressed in tissues 
that are important for uptake and elimination of toxic 
substances such as the intestine, the kidney, the liver, and 
the blood brain barrier  [3–7] .  BCRP and Pgp are localized 
in the apical membrane of intestinal cells, where they 
 limit the absorption of orally administered drugs and 
 ingested toxins such as the BCRP substrates PhIP (2-
 amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), ben-
zo [a]pyrene  [8] and the chlorophyll-derived phototoxin 
pheophorbide a  [9, 10] or the Pgp substrates digoxin, ci-
closporin or verapamil  [11–13] . These findings indicate 
that both transporters exhibit a role in maintaining the 
barrier function of the intestinal epithelium. Several 
drugs (such as dexamethasone  [14] and sulphasalazine 
 [15] ) used in the treatment of inflammatory bowel dis-
ease are transported by Pgp and BCRP.
 Previous studies with gene arrays and quantitative RT-
PCR have reported that MDR1/ABCB1 (the gene of Pgp), 
and BCRP are downregulated in patients with active ul-
cerative colitis (UC)  [16–19] . Genetic variation analysis of 
MDR1 indicates that this gene locus is associated with 
susceptibility for UC  [20, 21] .
 These studies did, however, not differentiate between 
the transporter expression patterns in tissue samples ob-
tained from inflamed or unaffected mucosa of the same 
individuals and did not take into account whether the 
patients with UC received previous or concomitant anti-
inflammatory treatment. Since it is well known that sev-
eral drugs such as the antimycobacterial drug rifampicin 
or the antidepressant St. John’s wort are able to change 
the expression of Pgp  [22, 23] , it is important to investi-
gate whether the medication used in UC might influence 
MDR1 and/or BCRP mRNA expression.
 Therefore, MDR1 and BCRP expression was investi-
gated in newly diagnosed untreated patients with UC, pa-
tients with UC not responding to anti-inflammatory 
medication, UC patients in remission and healthy con-
trols. In patients with active UC,  it was of special interest 
to evaluate transporter expression in unaffected and in-
flamed mucosa. We hypothesized that gene expression of 
MDR1 and BCRP may be altered in UC.
 Materials and Methods 
 Patient Characteristics 
 In this study, 12 patients with newly diagnosed UC, 11 pa-
tients with active UC (refractory to treatment), 11 patients in 
remission and 26 control subjects were enrolled after having giv-
en their informed consent. For detailed patient characteristics, 
see  table 1 . Diagnosis of patients with UC was based on a typical 
clinical history, laboratory findings as well as endoscopic and 
histological criteria. Tissue biopsies were sampled by experi-
enced gastroenterologists. From patients with active disease 
(newly diagnosed patients and patients with refractory disease) 
biopsies were taken from the inflamed and from the unaffected 
region. In two newly diagnosed patients, biopsies could only be 
obtained of the inflamed mucosa due to macroscopic signs of 
pancolitis. Unaffected areas were defined as mucosa regions 
without any macroscopic/endoscopic signs of inflammation (ul-
ceration, edema, discoloration, hemorrhagic appearance or mu-
cinous/fibrinous coating); these biopsies were obtained at least 
10–15 cm distant from the pathologic area. Control subjects had 
an indication for a gastrointestinal tract endoscopy within a 
cancer screening program .  Biopsy specimens were obtained 
during routine endoscopy from the colon, submerged in RNA-
later solution (Qiagen, Hilden, Germany) and stored at –80  ° C 
until further processing. The study protocol and consent forms 
were approved by the State Ethical Committee of Basel prior to 
the start of the study.
 Real-Time RT-PCR Analysis (TaqMan) 
 Total RNA was isolated from 2 biopsies from each subject. 
RNA was extracted using the RNeasy Mini Kit (Qiagen) following 
the instructions provided by the manufacturer. RNA was quanti-
fied with a GeneQuant photometer (Pharmacia, Uppsala, Swe-
den). After DNase I digestion (Gibco Life Technologies, Basel, 
Switzerland), 1.5   g of total RNA was reverse-transcribed by Su-
perscript (Gibco Life Technologies) according to the manufactur-
er’s protocol using random hexamers as primers.
 TaqMan analysis was carried out on a 7900HT Sequence De-
tection System (Applied Biosystems, Rotkreuz, Switzerland) as 
previously described in recent papers of our group  [4, 24, 25] . In 
brief, standards for mRNA quantification were obtained by clas-
sical PCR using duodenal cDNA as a template. Primers for gener-
ating the standards and primers/probes for TaqMan analysis were 
designed according to the guidelines of Applied Biosystems with 
the help of the Primer Express 2.0 software (corresponding se-
quences are displayed in  table 1 ). All samples were run in tripli-
cates and were quantified using a standard curve. Not reverse-
transcribed RNA served as a negative control. For each sample the 
transcript numbers of BCRP, MDR1 and of villin were deter-
mined. By calculating the ratio of BCRP/villin and MDR1/villin, 
the mRNA expression was normalized. This approach has been 
established to account for variations in the enterocyte content of 
biopsies  [3, 26] .
 Immunohistochemistry 
 Human duodenal tissue fragments were mounted in OCT 
compound (Sakura Finetek, Zooterwoude, The Netherlands), 
snap-frozen in liquid nitrogen and stored at –80 ° C. Frozen sec-
tions (5   m) were air dried overnight and a periodate-lysine 
paraformaldehyde solution (3%) was used for postfixation. Then 
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the sections were washed with washing solution (TBS/NaCl, 
Tween 0.05%) and incubated with normal horse serum for 30 min 
at room temperature as blocking solution. For BCRP staining, 
the tissue sections were incubated with a 1: 1,240 dilution of the 
BCRP monoclonal antibody BXP-21 (Alexis Biochemicals, Lau-
sen, Switzerland) overnight at 4 ° C or for Pgp staining with the 
Pgp monoclonal antibody ISB1-PGP with a 1: 50 dilution. Sam-
ples were washed three times with washing solution and incu-
bated with the horse antimouse IgG secondary antibody for 30 
min at room temperature. After three washes with the washing 
solution, a perhydrol solution [H 2 O 2 (0.3%), sodium azide (0.1%) 
in PBS] was used to destroy the endogenous peroxidase activity. 
The staining was performed with the avidin/biotinylated en-
zyme complex (ABC method) according to the manufacturer’s 
instructions (Vectastain, Elite kit, Vector Laboratories, Burlin-
gane, Calif., USA). For detection, 3-amino-9-ethylcarbazole, 
which forms a red end product, was used (Biogenex, San Ramon, 
Calif., USA). Sections which served as negative controls were 
treated equally, except that they were not incubated with the pri-
mary antibody.
 Semiquantitative analysis of Pgp and BCRP staining was per-
formed in biopsies of control subjects (Pgp n = 7; BCRP n = 4), of 
patients with newly diagnosed UC in inflamed (Pgp n = 4; BCRP 
n = 3) vs. unaffected tissue (Pgp n = 3; BCRP n = 3) as well as of 
patients with therapy-refractory UC in inflamed (Pgp n = 4; 
BCRP n = 3) vs. unaffected tissue (Pgp n = 3; BCRP n = 3) and of 
patients in remission (Pgp n = 6; BCRP n = 3). Rating of protein 
staining on blinded specimens was done by a trained pathologist. 
Expression levels were rated as follows: 0 = no expression, 1 = low, 
2 = intermediate, 3 = high expression.
 Statistics 
 All values were expressed as means  8 SEM. UC patients’ 
MDR1 and BCRP expression was compared with that of control 
subjects by analysis of variance and subsequent Dunnett multi-
comparison test. All comparisons were performed as two-sided 
comparisons using the SPSS for Windows software (version 14.0). 
The level of significance was set at p  ! 0.05.
 Results 
 BCRP and MDR1 mRNA Expression Is 
Downregulated in the Inflamed Mucosa of Patients 
with Active UC 
 BCRP, MDR1 and villin mRNA expression was ana-
lyzed  in 26  control subjects and compared with patients 
with newly diagnosed UC (10 biopsy specimens from un-
affected mucosa and 12 from inflamed mucosa), patients 
with active UC and refractory to anti-inflammatory 
medication (11 biopsy specimens from unaffected mu-
cosa and 12 from inflamed mucosa) and UC patients in 
remission without any signs of acute disease.
 BCRP in the inflamed mucosa of newly diagnosed un-
treated UC patients was reduced to 30% when compared 
with the unaffected mucosa ( fig. 1 a). Mean BCRP mRNA 
expression  8 SEM was  0.009  8 0.002  in  the inflamed 
and 0.032  8 0.005 in the unaffected mucosa. Similarly, 
in patients with active UC refractory to anti-inflamma-
tory treatment, BCRP mRNA expression was significant-
ly (p = 0.006) reduced to 35% in inflamed mucosa (0.009 
 8 0.003), when compared with control subjects (0.026  8 
0.0029; p = 0.005). Patients treated with 5-aminosalicy-
lates (n = 7) showed an 8-fold reduction in BCRP expres-
Table 1. Patient characteristics
Patients newly
diagnosed with
UC (n = 12)
Patients with active
UC refractory to 
therapy (n = 11)
Patients in
remission
(n = 11)
Control
subjects
(n = 26)
Median age (range), years 55 (27–78) 55 (27–77) 42 (24–69) 56 (24–78)
Sex 4 M/8 F 7 M/4 F 4 M/7 F 13 M/13 F
Mean BMI 8 SEM 23.980.9 24.581.5 24.380.9 27.881.2
Mean clinical activity index 8 SEM 5.280.7 6.880.9 1.480.5 –
Medication none none
Patients with aminosalicylates
>3 g/day – 7 2 –
2–3 g/day – – 1 –
Patients with steroids
>40 mg/day – 2 – –
10–39 mg/day – 1 – –
<10 mg/day – 1 1 –
Patients with immunosuppressive drug
Azathioprine 100–150 mg/day – 1 (+40 mg prednisone) 4 –
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sion in the inflamed mucosa (0.005  8 0.001) versus unaf-
fected mucosa (0.04  8 0.006) ,  whereas only an insignifi-
cant decrease for prednisone-treated patients (n = 4) was 
observed.
 Almost identical BCRP expression levels were observed 
in the unaffected mucosa of patients with active UC (new-
ly diagnosed and refractory to anti-inflammatory medi-
cation) and in the unaffected mucosa of control subjects. 
BCRP mRNA levels of UC patients in remission (0.040  8 
0.006) were higher compared with control subjects. This 
increase was borderline significant  (p = 0.054).
 Similar findings were observed for MDR1 mRNA ex-
pression. In inflamed mucosa of patients with active UC, 
independent if newly diagnosed or refractory to treat-
ment, MDR1 showed lower expression levels when com-
pared with the unaffected mucosa ( fig. 1 b). In control 
subjects, mean MDR1  8 SEM expression was  0.043  8 
0.003, in newly diagnosed UC patients 0.016  8 0.003 in 
the inflamed (p = 0.005) and 0.053  8 0.011 in the unaf-
fected mucosa. In therapy-refractory patients with the in-
flamed mucosa, mean MDR1/villin expression was 0.025 
 8 0.007 (which was borderline significantly lower than 
in controls, p = 0.091) and 0.042  8 0.006 in the unaf-
fected mucosa. Again, patients treated with 5-amino-
salicylates showed significantly reduced MDR1 expres-
sion in the inflamed mucosa, 0.011  8 0.002 versus 0.037 
 8 0.005 in the unaffected tissue. MDR1 expression in 
UC patients in remission (0.049  8 0.008) was compara-
ble to control subjects.
 BCRP and Pgp Levels Are Reduced in the Inflamed 
Mucosa in Patients with Active UC 
 Expression of BCRP and Pgp was evaluated by immu-
nohistochemistry in control subjects, newly diagnosed, 
and therapy-refractory patients with UC, as well as UC 
patients in remission. In the group of newly diagnosed 
and therapy-refractory patients, tissue samples obtained 
from inflamed mucosa and samples from unaffected mu-
cosal sites were analyzed separately.
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 Fig. 1.  a BCRP mRNA expression (BCRP/villin) in 26 healthy sub-
jects, in colonic tissue sections with no visible inflammation of 
10 newly diagnosed UC patients and in 12 acute inflamed tissue 
sections of newly diagnosed UC patients, in colonic tissue sec-
tions with no visible signs of inflammation of 11 therapy-refrac-
tory patients and in 12 acute inflamed tissue sections of therapy-
refractory patients, in tissue sections of 17 UC patients in remis-
sion. Data represent means  8 SEM. Statistical comparisons with 
controls were obtained.  b MDR1 mRNA expression (MDR1/vil-
lin) in 26 healthy subjects, in colonic tissue sections with no vis-
ible inflammation of 9 newly diagnosed UC patients and in 11 
tissue sections from acutely inflamed sites of newly diagnosed UC 
patients, in colonic tissue sections with no visible signs of inflam-
mation of 11 therapy-refractory patients and in 12 tissue sections 
from acutely inflamed sites of therapy-refractory patients, and in 
tissue sections obtained from 17 UC patients in remission. Data 
represent means  8 SEM. Statistical comparisons with controls 
were obtained. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
5/
20
17
 1
0:
12
:3
4 
AM
 Gutmann et al.
 
Digestion 2008;78:154–162158
 As expected, both ABC transporter proteins were lo-
calized on the apical membrane of the epithelial cells (see 
 fig. 3, 4 ). Pgp and BCRP were significantly reduced in in-
flamed mucosa of newly diagnosed as well as therapy-re-
fractory patients. Protein expression in the unaffected 
tissue of control subjects was comparable with expression 
in unaffected tissue of UC patients with active disease as 
well as in UC patients in remission ( fig. 2 ). In tissue sec-
tions from the inflamed mucosa, BCRP expression was 
reduced by 63% in newly diagnosed and was even com-
pletely abolished in therapy-refractory UC patients when 
compared with control subjects ( fig. 2 a). Similarly, Pgp 
expression was reduced by about 85% in the inflamed 
mucosa of patients with active UC compared with control 
subjects ( fig. 2 b).
 Representative pictures of immunohistochemistry 
with staining for BCRP are displayed in  figure 3 and for 
Pgp in  figure 4 .
 Discussion 
 The results of this study demonstrate that  expression 
of BCRP and MDR1 is downregulated in patients with 
UC on the transcriptional and protein levels, but only in 
the inflamed mucosa. On the other hand, both transport-
ers show a similar expression level in gut biopsies from 
unaffected sites of patients with active UC, in samples 
from patients in remission and in biopsies from nonin-
flamed parts of the gut of control subjects. The reduction 
in transporter expression in inflamed mucosa of untreat-
ed newly diagnosed UC patients was similar to that in 
patients who have failed treatment with 5-ASA or corti-
costeroids, which suggests that this reduction is largely 
dependent on the inflammation rather than the anti-in-
flammatory treatment.
 Efflux transport proteins are important components 
of the intestinal barrier against bacterial toxins, carcino-
gens and drugs  [3–7, 9–13] . Altered expression of trans-
port proteins and/or altered function of these proteins 
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 Fig. 2.  a BCRP amount in selected healthy subjects, in colonic tis-
sue sections with no visible signs of inflammation of 10 newly 
diagnosed UC patients and in 12 tissue sections obtained from 
acutely inflamed sections of newly diagnosed UC patients, in co-
lonic tissue sections with no visible signs of inflammation of 11 
therapy-refractory patients and in 12 tissue samples from acutely 
inflamed sections of therapy-refractory patients, in tissue sec-
tions of 17 UC patients in remission. Data represent means  8 
SEM. Statistical comparisons with controls were obtained.  b Pgp 
amount in selected healthy subjects, in colonic tissue sections 
with no visible signs of inflammation of 10 newly diagnosed UC 
patients and in 12 tissue sections obtained from acutely inflamed 
sites of newly diagnosed UC patients, in colonic tissue sections 
obtained from sites with no visible signs of inflammation of 11 
therapy-refractory patients and in 12 tissue sections obtained 
from acutely inflamed sites of therapy-refractory patients, in tis-
sue sections of 17 UC patients in remission. Data represent means 
 8 SEM. Statistical comparisons with controls were obtained. 
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have been proposed to contribute to the pathogenesis of 
inflammatory disorders  [16–21] . Here, we document that 
two of the efflux transporters of importance for the bar-
rier function of the gastrointestinal mucosa, Pgp and 
BCRP, are expressed at markedly reduced levels in the 
inflammatory areas of the colon in patients with UC. 
This is in keeping with a recent study by Englund et al. 
 [18] who also showed that BCRP and Pgp expression was 
reduced in inflamed tissue of UC patients that were tak-
ing anti-inflammatory drugs. We furthermore demon-
strate that BCRP mRNA levels of patients with UC in 
remission are increased as compared with control sub-
jects. These findings suggest that the inflammation itself 
might be responsible for the observed effects. Inflamma-
tion is known to suppress the expression and activity of 
several efflux transporters; also, the expression and func-
tion of intestinal mdr1 and mrp2 are reduced in a rat 
model of intestinal inflammation. Here, we extend these 
observations by showing that BCRP and MDR1 expres-
sion is reduced in the inflamed part compared with non-
inflamed tissue in individuals with active disease. Final-
ly, the effect of drug treatment on the expression of these 
two transporters is related to their anti-inflammatory ac-
tivity: patients that were treated with 5-aminosalicylates 
(n = 7) and did not respond to this treatment showed a 
considerable suppression in BCRP and MDR1 expression 
in the inflamed mucosa when compared with the unaf-
fected area. On the other hand, patients treated with 
prednisone (n = 4) showed only an unremarkable and in-
significant decrease in both transporters. Although pred-
nisone was identified as a substrate for Pgp  [27] , it is not 
known to induce Pgp or BCRP. We conclude, therefore, 
that the reduced expression observed for the two trans-
porters is a direct result of the inflammation. The find-
a b
c d
fe
 Fig. 3. Immunohistochemical staining of 
BCRP on the apical membrane of  human 
duodenal epithelial cells using the BCRP 
antibody BXP-21.  a Healthy subject.
 b Newly diagnosed UC patient, nonin-
flamed tissue.  c Newly diagnosed UC pa-
tient, inflamed tissue.  d Therapy-refrac-
tory UC patient, noninflamed tissue.
 e Therapy-refractory UC patient, inflamed 
tissue.  f UC patient in remission. 
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ings furthermore suggest that the two transporters are 
most likely not involved in the pathogenesis of UC.
 It is well known that the expression and activity of a 
number of hepatic efflux transporters such as MRP2, 
MRP3, MRP4, and organic anion-transporting polypep-
tides are diminished during inflammatory processes 
 [28–30] . Alterations in transporter expression do not 
only occur in the liver, but also in kidney and intestine. 
Recently, we reported a decrease in BCRP expression in 
cholestatic patients  [31] indicating that BCRP downregu-
lation might be a phenomenon also observed in other 
gastrointestinal diseases. In vitro data indicate that the 
transcriptional regulation of BCRP is mediated via the 
Ah receptor  [8] , whereas Pgp is regulated by PXR  [32] . 
 Several proinflammatory cytokines have been shown to 
influence transporter gene expression  [33, 34] . In fact, 
Evseenko et al.  [35] found that incubation of primary 
term trophoblasts with TNF-  or IL-1  decreased mRNA 
and protein expression of Pgp and BCRP to 40–50%, re-
spectively. They could also show that TNF-  affects 
BCRP expression also at a functional level leading to in-
creased mitoxantrone accumulation  [35] . The mecha-
nisms leading to the observed downregulation have to be 
elaborated.
 As both transporters are potent efflux pumps for a va-
riety of toxic compounds, a diminished expression might 
disturb the intestinal barrier and the excretory function 
of the gut. A reduced intestinal expression of BCRP and 
Pgp in inflamed mucosal sites could substantially con-
tribute to the accumulation of carcinogens and other 
harmful substances (bile acids) in enterocytes. This in 
turn might partly explain the observation that patients 
with UC have a higher risk of developing colorectal car-
cinomas  [36, 37] .
a b
c d
fe
 Fig. 4. Immunohistochemical staining of 
Pgp on the apical membrane of  human du-
odenal epithelial cells using the Pgp anti-
body ISB1-PGP.  a Healthy subject.  b New-
ly diagnosed UC patient, noninflamed 
 tissue.  c Newly diagnosed UC patient, in-
flamed tissue.  d Therapy-refractory UC 
patient, noninflamed tissue.  e Therapy-re-
fractory UC patient, inflamed tissue.  f UC 
patient in remission. 
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 In conclusion, we have shown that patients with UC 
exhibit a decreased expression of BCRP and MDR1, both 
on the mRNA and protein levels in inflamed sites of the 
mucosa. The data together with published information 
suggest that the inflammatory process is responsible for 
the reduced levels. A major role in the pathogenesis of
UC is unlikely. However, a decreased expression of these 
transporters might increase the accumulation of food-
derived carcinogens and toxins and might influence the 
pharmacokinetics and effects of anti-inflammatory drugs 
used in the treatment of UC.
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